Agenda

Date and TimeTitle
Sep 14, 2022
5:00pm - 7:12pm (Eastern)
Session I: Acute Leukemias

5:00 pm ET | Welcome and Introductions
Courtney D. DiNardo, MD, MSCE

5:05 pm ET | Intensive Frontline Therapy for AML
Harry P. Erba, MD, PhD

5:20 pm ET | Lower-Intensity Frontline Therapy for AML
Courtney D. DiNardo, MD, MSCE

5:35 pm ET | Relapsed/Refractory AML
Naval G. Daver, MD

5:50 pm ET | Panel Discussion and Audience Q&A
Courtney D. DiNardo, MD, MSCE, Moderator
Naval G. Daver, MD
Harry P. Erba, MD, PhD

6:00 pm ET | Philadelphia-Positive ALL
Elias J. Jabbour, MD

6:15 pm ET | Philadelphia-Negative ALL: Immunotherapy in the Frontline
Aaron C. Logan, MD, PhD

6:30 pm ET | Relapsed/Refractory ALL: Sequencing vs CAR T-Cell Therapy
Jae H. Park, MD

6:45 pm ET | Assessing Measurable Residual Disease in Acute Leukemias
Jessica Leonard, MD

7:00 pm ET | Panel Discussion and Audience Q&A
Elias J. Jabbour, MD, Moderator
Jessica Leonard, MD
Elias J. Jabbour, MD
Aaron C. Logan, MD, PhD

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) (Universal Activity Number: JA0007105-0000-22-165-L01-P).

Sep 14, 2022
7:12pm - 7:25pm (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 14, 2022
7:25pm - 9:00pm (Eastern)
Session II: Myelodysplastic Syndrome and Myeloproliferative Neoplasms

7:25 pm ET | Welcome and Introductions
Elias J. Jabbour, MD

7:30 pm ET | Advances in Newly Diagnosed Higher-Risk MDS
Guillermo Garcia-Manero, MD

7:45 pm ET | Advances in MDS Management Following HMA-Failure
Amer Zeidan, MBBS, MHS

8:00 pm ET | Panel Discussion and Audience Q&A
Elias J. Jabbour, MD, Moderator
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS, MHS

8:15 pm ET | Optimizing the Use of JAK Inhibitors in the Management of Myelofibrosis
John Mascarenhas, MD

8:30 pm ET | Novel Agents in Polycythemia Vera and Essential Thrombocythemia
Srdan Verstovsek, MD, PhD

8:45 pm ET | Panel Discussion and Audience Q&A
Elias J. Jabbour, MD, Moderator
John Mascarenhas, MD
Srdan Verstovsek, MD, PhD

9:00 pm ET | Day Adjourns

Supported by an educational grant from CTI BioPharma Corp.
Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) (Universal Activity Number: JA0007105-0000-22-167-L01-P).

Sep 15, 2022
4:00pm - 5:00pm (Eastern)
CME/CE Independent Symposium: The Non-Hodgkin Lymphoma Case Clinic

Speakers:

Julie M. Vose, MD, MBA
Gilles Salles, MD, PhD
Kami Maddocks, MD

Program Description: The field of Non-Hodgkin Lymphona is rapidly and continually evolving with new treatment approaches and novel therapies. In this interactive symposium, our expert faculty discuss patient case management together with effective therapies. In addition, they will review and contextualize clinical data on emerging therapies for multiple myeloma. Attendees will have the opportunity to engage through real-time polling, pre-post questions, and a Q&A session.

Click here to claim credit

Supported by an independent educational grant from Regeneron Pharmaceuticals

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live event for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.00 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-300-L01-P).

Sep 15, 2022
5:00pm - 5:30pm (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 15, 2022
5:30pm - 6:30pm (Eastern)
Session III: Keynote

5:30 pm ET | Health Equity in Hematologic Malignancies
Edith Mitchell, MD, MACP, FCPP, FRCP

Supported by an educational grant from CTI BioPharma Corp.
Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Janssen Biotech, Inc.
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Supported by an educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) (Universal Activity Number: JA0007105-0000-22-164-L01-P).

Sep 15, 2022
6:30pm - 7:55pm (Eastern)
Session IV: Non-Hodgkin Lymphomas

6:30 pm ET | Welcome and Introductions
Christopher Flowers, MD, MS

6:35 pm ET | Evolving Treatment Landscape in Diffuse Large B Cell Lymphoma
Christopher Flowers, MD, MS, Moderator
Gilles Salles, MD, PhD

6:50 pm ET | A Comprehensive Update on Mantle Cell Lymphoma
Christopher Flowers, MD, MS, Moderator
Kami Maddocks, MD

7:05 pm ET | The Latest Updates in Follicular Lymphoma
Christopher Flowers, MD, MS, Moderator
Loretta Nastoupil, MD

7:20 pm ET | Panel: Case Discussion
Christopher Flowers, MD, MS, Moderator
Amy Goodrich, RN, MSN, CRNP-A, Moderator
Gilles Salles, MD, PhD
Kami Maddocks, MD

7:40 pm ET | Panel Discussion and Audience Q&A
Christopher Flowers, MD, MS, Moderator
Gilles Salles, MD, PhD
Kami Maddocks, MD

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-22-161-L01-P).

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change. 

Sep 15, 2022
7:55pm - 8:10pm (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 15, 2022
8:10pm - 9:29pm (Eastern)
Session V: Hodgkin Lymphoma

8:10 pm ET | Welcome and Introductions
Christopher Flowers, MD, MS

8:15 pm ET | Approaches to Newly Diagnosed Hodgkin Lymphoma
Pamela Allen, MD, MSc

8:35 pm ET | Immunotherapy Approaches
Sairah Ahmed, MD

8:55 pm ET | Weighing Outcomes vs Toxicities With Lymphoma Treatment
Michael Buege, PharmD, BCOP

9:15 pm ET | Audience Q&A
Christopher Flowers, MD, MS, Moderator
Sairah Ahmed, MD
Michael Buege, PharmD, BCOP

9:30 pm ET | Day Adjourns

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-22-162-L01-P).

Sep 16, 2022
1:30pm - 2:16pm (Eastern)
NINLARO® (ixazomib): Durable Strength When Navigating the Difficulties of Multiple Myeloma in the Real World

Sponsored by Takeda

This is a Non CME/CE Presentation.

Sep 16, 2022
3:00pm - 4:15pm (Eastern)
Session VI: T-Cell Lymphomas

3:00 pm ET | Welcome and Introductions
Steven Horwitz, MD

3:05 pm ET | Novel Approaches in Cutaneous and Peripheral T-Cell Lymphomas
John Reneau, MD, PhD

3:25 pm ET | Case Study: Peripheral T-Cell Lymphoma
Kerry Savage, BSc, MD, MSc, FRCPC

3:45 pm ET | Case Study: Cutaneous T-Cell Lymphoma
Alison Moskowitz, MD

4:00 pm ET | Panel Discussion and Audience Q&A
Steven Horwitz, MD, Moderator
Kerry Savage, BSc, MD, MSc, FRCPC
John Reneau, MD, PhD

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-22-163-L01-P).

Sep 16, 2022
4:15pm - 4:30pm (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 16, 2022
4:30pm - 6:20pm (Eastern)
Session VII: Chronic Leukemias

4:30 pm ET | Welcome and Introductions
Courtney D. DiNardo, MD, MSCE

4:35 pm ET | Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate - Pro
Michael J. Mauro, MD

4:45 pm ET | Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate - Con
Jerald Radich, MD

4:55 pm ET | Sequencing Treatments in Relapsed/Refractory CML
Hagop M. Kantarjian, MD

5:10 pm ET | Audience Q&A
Courtney D. DiNardo, MD, MSCE, Moderator
Hagop M. Kantarjian, MD
Michael J. Mauro, MD
Jerald Radich, MD

5:20 pm ET | Frontline CLL Management: Chemoimmunotherapy vs BTK Inhibitors
Nitin Jain, MD

5:35 pm ET | Management of Relapsed/Refractory CLL
Anthony Mato, MD, MSCE

5:50 pm ET | Managing Oral Medications in Chronic Leukemias
Shilpa Paul, PharmD, BCOP

6:05 pm ET | Audience Q&A
Courtney D. DiNardo, MD, MSCE, Moderator
Nitin Jain, MD
Anthony R. Mato, MD, MSCE
Shilpa Paul

6:15 pm ET | Day Adjourns

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.75 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) (Universal Activity Number: JA0007105-0000-22-166-L01-P).

Sep 17, 2022
8:00am - 9:00am (Eastern)
CME/CE Independent Symposium: The Multiple Myeloma Case Clinic

Speakers: Caitlin Costello, MD
Shaji Kumar, MD
Krina Patel, MD, MS

Program Description: The field of multiple myeloma (MM) is rapidly and continually evolving with new treatment approaches and novel therapies. In this interactive symposium, our expert faculty will discuss patient case management along with effective therapies. In addition, they will review and contextualize clinical data on emerging therapies for multiple myeloma. Attendees will have the opportunity to engage through real-time polling, pre-post questions, and a Q&A session.

Click here to claim credit

Supported by an independent educational grant from GlaxoSmithKline and Regeneron Pharmaceuticals

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live event for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.00 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-313-L01-P).

Sep 17, 2022
9:00am - 9:15am (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 17, 2022
9:15am - 12:04pm (Eastern)
Session VIII: Multiple Myeloma

9:15 am ET | Welcome and Introductions
Shaji Kumar, MD

9:20 am ET | The Smoldering Myeloma Debate: To Treat or Not to Treat - Treat
Shaji Kumar, MD, Moderator
Nisha Joseph, MD

9:30 am ET | The Smoldering Myeloma Debate: To Treat or Not to Treat - Observe
Shaji Kumar, MD, Moderator

9:40 am ET | Panel Discussion and Audience Q&A
Shaji Kumar, MD, Moderator
Nisha Joseph, MD

9:45 am ET | Advances in the Treatment of Newly Diagnosed Multiple Myeloma
Shaji Kumar, MD, Moderator
Ajay Nooka, MD, MPH, FACP

10:00 am ET | Approaches to Maintenance Therapy in Multiple Myeloma
Shaji Kumar, MD, Moderator
Amrita Krishnan, MD, FACP

10:15 am ET | Keys to Response Assessment in Multiple Myeloma
Shaji Kumar, MD, Moderator

10:25 am ET | Panel Discussion and Audience Q&A
Shaji Kumar, MD, Moderator
Ajay Nooka, MD, MPH, FACP
Amrita Krishnan, MD, FACP

10:30 am ET | Management of Early Relapsed/Refractory Multiple Myeloma (+5 min Q&A)
Shaji Kumar, MD, Moderator
Sagar Lonial, MD, FACP

11:00 am ET | Evolving Treatment Strategies in Late Relapsed/Refractory Multiple Myeloma (+5min Q&A)
Shaji Kumar, MD, Moderator
Krina Patel, MD

11:30 am ET | Supportive Care Considerations for Patients With Multiple Myeloma
Shaji Kumar, MD, Moderator
Anita D'Souza, MD

11:40 am ET | Interprofessional Myeloma Management: A Case-Based Discussion
Shaji Kumar, MD, Moderator
Charise Gleason, MSN, NP-C, AOCNP
Kathryn Maples, PharmD, BCOP

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Janssen Biotech, Inc.
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.75 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 2.75 contact hour(s) (0.275 CEUs) (Universal Activity Number: JA0007105-0000-22-168-L01-P).

IPCE

This activity was planned by and for the healthcare team, and learners will receive 2.75 Interprofessional Continuing Education (IPCE) credit for learning and change. 

Sep 17, 2022
12:00pm - 12:15pm (Eastern)
Break

Click HERE to visit the Networking Forum.

Sep 17, 2022
12:15pm - 1:50pm (Eastern)
Session IX: Complex Patient Care Topics in Hematologic Malignancies

12:15 pm ET | Welcome and Introductions
Sandra Kurtin, PhD, ANP-C, AOCN
Kathryn Maples, PharmD, BCOP

12:20 pm ET | Addressing Challenges in Care: An Interprofessional Roundtable
Sandra Kurtin, PhD, ANP-C, AOCN, Moderator
Kathryn Maples, PharmD, BCOP, Moderator
Sairah Ahmed, MD

1:30 pm ET | Panel Discussion and Audience Q&A
Sandra Kurtin, PhD, ANP-C, AOCN, Moderator
Kathryn Maples, PharmD, BCOP, Moderator
Sairah Ahmed, MD

1:50 pm ET | Day Adjourns

Supported by an educational grant from GlaxoSmithKline
Supported by an educational grant from Incyte Corporation
Supported by an educational grant from Janssen Biotech, Inc.
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs.

For Pharmacists
Medscape designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) (Universal Activity Number: JA0007105-0000-22-169-L01-P).

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.